Ifinatamab Deruxtecan Demonstrated Clinically Meaningful Response Rates in Patients with Extensive-Stage Small Cell Lung Cancer in IDeate-Lung01 Phase 2 Trial – Business Wire
- Ifinatamab Deruxtecan Demonstrated Clinically Meaningful Response Rates in Patients with Extensive-Stage Small Cell Lung Cancer in IDeate-Lung01 Phase 2 Trial Business Wire
- Ifinatamab deruxtecan demonstrates high response rate in previously treated extensive-stage small cell lung cancer Medical Xpress
- Ifinatamab deruxtecan shows 48% response rate in small cell lung cancer Investing.com